Overview
Status
Active
Registry date
2021-05-05
Registered address
ul. Stanisława Żaryna 2B, 02-593 Warszawa, Poland
Electronic delivery address
AE:PL-85930-79323-IAUGJ-32
Financials
Revenue history (in k)
Data and insights are generated automatically based on financial statements and may contain errors. This analysis is for informational purposes only and does not constitute an official assessment of the company's credibility or business advice.
Statistics
How the company ranks by revenue within its industry, region and across Poland in 2025.
Results vs industry
Revenue
This companyUSD 10.40kMedianUSD 38.54kAverageUSD 2.32m
Net profit
This companyUSD 4.57kMedianUSD -1.56kAverageUSD -88.44k
Operating costs
This companyUSD 5.50kMedianUSD 56.03kAverageUSD 2.29m
Assets
This companyUSD 15.42kMedianUSD 119.99kAverageUSD 2.73m
Industry
Bank accounts
Registered as a VAT taxpayer on 2021-07-01. Active
54 2490 0005 0000 4530 1278 0218
Debt
No entries in the National Debtors Register (KRZ). No proceedings in KRZ
Public aid
No public aid cases recorded in the last 10 years.
Tenders
No recorded participation in tenders.
Authorized Representatives
Wojciech Jacek Ciesielski – President of the Management Board
Manner of representation
The company is represented by the President of the Management Board independently, or by a member of the management board jointly with a commercial proxy.
Ownership
| Owner | Shares | Share value | Stake |
|---|---|---|---|
| 17 | $229.61 | 15.3153% | |
Magdalena Bujalska Zadrożny (54) | 20 | $270.12 | 18.018% |
Ryszard Nowaczyk (68) | 12 | $162.07 | 10.8108% |
| 62 | $837.39 | 55.8559% |
Beneficial owners
| Person | Rights |
|---|---|
Competitors
| Name | Revenue | Website | ||
|---|---|---|---|---|
| Frontline BiosciencesS.A. | $219,186.29 | frontlinebiosciences.com | ||
| AI Corelabsp. z o.o. | $128,365.55 | aicorelab.com | ||
| ModicaP.S.A. | $103,400.72 | modica.bio | ||
| WPD Pharmaceuticalssp. z o.o. | $90,822.78 | wpdpharmaceuticals.com | ||
| WPD PharmaceuticalsS.A. | $87,561.70 | wpdpharmaceuticals.pl | ||
| Stenocoatsp. z o.o. | $36,665.21 | stenocoat.com | ||
| Platforma Badań Genetycznychsp. z o.o. | $28,558.39 | zdrowegeny.pl | ||
| Bioselsp. z o.o. | $19,100.32 | selol.pl | ||
| Omnisepticasp. z o.o. | $3,475.29 | omniseptica.com | ||
| Wavex Energysp. z o.o. | $142.33 | wavexenergy.com |
Change history
| Date | Event | |
|---|---|---|
| 2026-03-19 | Address change (Ul. Postępu 21b, 02-676, Warszawa → Ul. Stanisława Żaryna 2b, 02-593, Warszawa) | |
| 2025-08-14 | Share capital change (5,450.00 PLN → 5,550.00 PLN) | |
| 2024-11-19 | Share capital change (5,250.00 PLN → 5,450.00 PLN) | |
| 2024-10-08 | Share capital change (5,100.00 PLN → 5,250.00 PLN) | |
| 2024-02-21 | Share capital change (5,000.00 PLN → 5,100.00 PLN) |
FAQ
The main business activity of Bioxyma focuses on research and experimental development on biotechnology.
The company was registered in the Polish National Court Register (KRS) on May 5, 2021.
The headquarters is located at: ul. Stanisława Żaryna 2B, 02-593 Warszawa.
The management board consists of: Wojciech Jacek Ciesielski (President of the Management Board).
The share capital of the company is PLN 5,550 (approx. $1,499).
The latest available financial statement covers the period from January 1, 2025 to December 31, 2025.
The company reported a revenue of $10,402 in 2025, which is a decrease of 89.3% compared to 2024.
Yes, in 2025 the company was profitable, achieving a net profit of $4,571.
Last updated: 2026-03-22
